Arcoma (ARCOMA) Q4 2024 earnings summary

Executive summary

• Ended 2024 with strong profitability and record annual profit, driven by focus on higher-margin deals and cost control.

• EBITDA for the year increased 70% year-over-year, with an EBITDA margin of 13% (up from 8%).

• Established a debt-free position, strengthening financial stability and flexibility for future growth.

Financial highlights

• Q4 net sales: 36,802 KSEK (down from 51,327 KSEK in Q4 2023, which was exceptionally strong).

• Q4 EBITDA: 5,017 KSEK (5,710 KSEK last year); Q4 EBITDA margin: 13% (11%).

• Full-year net sales: 156,807 KSEK (163,015 KSEK in 2023); full-year EBITDA: 21,590 KSEK (12,747 KSEK).

• Full-year pre-tax profit: 13,768 KSEK (3,132 KSEK); EPS: 0.85 SEK (0.19 SEK).

• Q4 gross margin: 38% (33% last year), supported by favorable product and geographic mix.

Outlook and guidance

• Platform established for future growth with continued focus on profitability.

• Ongoing evaluation of acquisition opportunities and development projects for 2025.

• Underlying demand in North America remains strong; EMEA market shows signs of improvement.